Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 10/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495994 | 1.00 | GAA (0.55) | GAARAB9AHPGDSGABRA5BAZ2B | |
| SCHEMBL16495704 | 0.91 | NOS2 (0.54) | GAARAB9AHPGDSGABRA5NOS2 | |
| SCHEMBL16495705 | 0.91 | NOS2 (0.54) | GAARAB9AHPGDSGABRA5NOS2 | |
| SCHEMBL16495907 | 0.88 | ROCK2 (0.51) | GAARAB9AHPGDSGABRA5LNPEP | |
| SCHEMBL16495420 | 0.88 | HPGDS (0.48) | GAARAB9AHPGDSGABRA5NOS2 | |
| SCHEMBL16495908 | 0.88 | ROCK2 (0.51) | GAARAB9AHPGDSGABRA5LNPEP | |
| SCHEMBL16495422 | 0.88 | HPGDS (0.48) | GAARAB9AHPGDSGABRA5NOS2 | |
| SCHEMBL6029369 | 0.85 | GAA (0.64) | GAARAB9AHPGDSGABRA5BAZ2B | |
| SCHEMBL28603072 | 0.84 | GAA (0.71) | GAARAB9ANOS2PYGL | |
| SCHEMBL6029601 | 0.83 | RAB9A (0.64) | GAARAB9AHPGDSGABRA5NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | GAA 887/4885RAB9A 2122/4885HPGDS 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.